1 / 6

2022 Kogenate FS Industry (Hemophilia A and B) Report

Buy the report "Kogenate FS (Hemophilia A and B) - Forecast and Market Analysis to 2022" at US $3495 for a Single User PDF License from RnR Market Research Reports Library.

joemacdy
Télécharger la présentation

2022 Kogenate FS Industry (Hemophilia A and B) Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Kogenate FS (Hemophilia A and B) – Forecast and Market Analysis to 2022byGlobalData Explore all reports for “Hematology Therapeutics ” market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/hematology-therapeutics © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  2. Kogenate FS (Hemophilia A and B) – Forecast and Market Analysis to 2022 The collection of ‘Hematology Therapeutics ’ market research reports has a new addition of “Kogenate FS (Hemophilia A and B) – Forecast and Market Analysis to 2022” on RnRMarketResearch.com. The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145252. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  3. Kogenate FS (Hemophilia A and B) – Forecast and Market Analysis to 2022 Kogenate FS is marketed in the US by Bayer Healthcare and in the 5EU by Bayer Pharma AG under the brand name Kogenate Bayer. It is also marketed in the US by CSL Behring under the brand name Helixate FS. It is marketed in the 5EU as HelixateNexGen by Bayer Pharma AG and CSL Behring. Scope Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Kogenate Fs including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Kogenate Fs for the top nine countries from 2012 to 2022. Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China. Complete report available @ http://www.rnrmarketresearch.com/kogenate-fs-hemophilia-a-and-b-forecast-and-market-analysis-to-2022-market-report.html . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  4. Kogenate FS (Hemophilia A and B) – Forecast and Market Analysis to 2022 Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of Kogenate Fs performance Obtain sales forecast for Kogenate Fs from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China) Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145252 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  5. Kogenate FS (Hemophilia A and B) – Forecast and Market Analysis to 2022 Table of Contents 1 Table of Contents 5 2 Introduction 8 3 Disease Overview 12 4 Disease Management 18 5 Competitive Assessment 23 6 Kogenate FS / Helixate FS (Antihemophilic Factor  (Recombinant)) 28 7 Appendix 33 Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145252 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  6. Kogenate FS (Hemophilia A and B) – Forecast and Market Analysis to 2022 For more details contact Mr. PriyankTiwari:sales@rnrmarketresearch.com/ +18883915441 RnR Market Research RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnR  Market Research library has syndicated reports by leading market research  publishers across the globe. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

More Related